- Home
- SPFI vs CGEM Comparison
SPFI vs CGEM Comparison
Compare SPFI & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPFI
- CGEM
- Stock Information
- Founded
- SPFI 1941
- CGEM 2016
- Country
- SPFI United States
- CGEM United States
- Employees
- SPFI N/A
- CGEM N/A
- Industry
- SPFI Major Banks
- CGEM Biotechnology: Pharmaceutical Preparations
- Sector
- SPFI Finance
- CGEM Health Care
- Exchange
- SPFI Nasdaq
- CGEM Nasdaq
- Market Cap
- SPFI 647.7M
- CGEM 730.2M
- IPO Year
- SPFI 2019
- CGEM 2021
- Fundamental
- Price
- SPFI $33.80
- CGEM $9.03
- Analyst Decision
- SPFI Buy
- CGEM Strong Buy
- Analyst Count
- SPFI 2
- CGEM 7
- Target Price
- SPFI $40.50
- CGEM $32.50
- AVG Volume (30 Days)
- SPFI 28.7K
- CGEM 432.6K
- Earning Date
- SPFI 01-24-2025
- CGEM 03-13-2025
- Dividend Yield
- SPFI 1.77%
- CGEM N/A
- EPS Growth
- SPFI N/A
- CGEM N/A
- EPS
- SPFI 2.92
- CGEM N/A
- Revenue
- SPFI $190,870,000.00
- CGEM N/A
- Revenue This Year
- SPFI N/A
- CGEM N/A
- Revenue Next Year
- SPFI $7.23
- CGEM N/A
- P/E Ratio
- SPFI $11.58
- CGEM N/A
- Revenue Growth
- SPFI N/A
- CGEM N/A
- 52 Week Low
- SPFI $24.05
- CGEM $8.92
- 52 Week High
- SPFI $40.91
- CGEM $30.19
- Technical
- Relative Strength Index (RSI)
- SPFI 36.67
- CGEM 30.40
- Support Level
- SPFI $35.09
- CGEM $9.06
- Resistance Level
- SPFI $37.35
- CGEM $9.51
- Average True Range (ATR)
- SPFI 0.97
- CGEM 0.50
- MACD
- SPFI -0.20
- CGEM -0.05
- Stochastic Oscillator
- SPFI 0.00
- CGEM 6.18
About SPFI South Plains Financial Inc.
South Plains Financial Inc operates as a bank holding company. The company provides a wide range of commercial and consumer financial services to small and medium-sized businesses and individuals. The principal business activities include commercial and retail banking, along with insurance, investment, trust, and mortgage services. The company has two reportable segments: banking and insurance.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, create differentiated ideas, identify the appropriate targets, and select the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications.